Nursing care
First-Pass Metabolism, explained for the bedside and the exam
Written and reviewed by Dana Whitfield, RN, MSN · 6 min read · Updated September 2026
Short answer
First-pass metabolism is the reduction in an oral drug's active concentration as it passes through the intestinal wall and liver before reaching systemic circulation. It is why an oral dose is often far larger than the IV dose of the same drug. Route changes bioavailability, not just speed of onset.
Defining it precisely
First-pass metabolism refers to the metabolism of an orally administered drug that occurs before it ever reaches systemic circulation. Absorbed drug travels from the gut lumen into the portal circulation, and the portal vein delivers it straight to the liver. Hepatic enzymes, chiefly the cytochrome P450 family, metabolise a portion of the dose on that first pass. Some drugs are also metabolised by enzymes in the gut wall itself before absorption is even complete.
The practical consequence is bioavailability: the fraction of the administered dose that reaches systemic circulation unchanged. A drug with extensive first-pass metabolism might have an oral bioavailability of 10 to 30 percent, meaning most of the dose is inactivated before it can act. This is exactly why the oral dose of a drug is often far larger than the IV dose of the same drug. IV administration bypasses the gut and liver entirely, so the full dose enters circulation. Nitroglycerin, morphine, and propranolol all illustrate this gap between oral and IV dosing.
The exceptions that matter
Not every route avoids first-pass metabolism, and not every drug is affected by it equally. Sublingual, buccal, transdermal, rectal (partially), and inhaled routes bypass or reduce hepatic first-pass effect because they allow at least partial absorption directly into systemic venous drainage rather than the portal vein. This is why sublingual nitroglycerin acts within minutes for angina, while an equivalent oral dose would be largely inactivated before reaching the coronary circulation.
Prodrugs are the clearest exception to the general rule that first-pass metabolism only reduces drug effect. A prodrug is inactive until hepatic metabolism converts it to its active form, so first-pass metabolism is required for the drug to work at all. Enalapril, converted to enalaprilat, and codeine, converted to morphine, depend on this conversion. Genetic variation in the enzymes involved, particularly CYP2D6, means some patients convert codeine poorly and get little analgesic effect, while a small proportion are ultra-rapid metabolisers at risk of toxicity.
Using it to prioritise
When a patient is switched from IV to oral therapy, or the reverse, first-pass metabolism should shape your expectation of dose equivalence. A straight one-to-one substitution of an oral dose for an IV dose of the same drug will usually underdose the patient, and vice versa. Check whether the prescriber has adjusted the dose to match the route, and question an order that has not.
First-pass metabolism also affects how quickly you expect a therapeutic or toxic effect to appear. A sublingual or IV drug with high hepatic extraction will act faster and more predictably than the oral form of the same drug, because none of the portal-to-liver step is in play. In an unstable patient, this is a reason to favour routes that bypass first-pass metabolism when the prescriber's order allows it, since onset and blood level are more predictable.
Traps in exam wording
NCLEX-style items often test whether you can identify first-pass metabolism as the reason oral and IV doses of the same drug differ, without using the term explicitly. A stem describing a much smaller IV dose than the oral dose for the same drug is testing this concept even if it never says the phrase. Read for the underlying pharmacokinetic principle, not just the vocabulary.
Watch for items that describe a drug requiring hepatic activation and ask why hepatic impairment reduces its effect. This is testing prodrug conversion, the exception to the usual first-pass pattern, and a wrong answer will treat it like every other drug that loses potency through the liver. Distinguish first-pass metabolism, which happens before systemic circulation, from ongoing hepatic clearance of a drug already in circulation. Items sometimes blur these two mechanisms, and only one of them explains the oral-versus-IV dose gap.
Examples from practice
Propranolol has an oral bioavailability much lower than its IV form because of extensive hepatic first-pass metabolism, which is one reason oral beta-blocker doses look large next to IV cardiac doses. Morphine shows the same pattern: oral morphine doses are typically two to three times the equivalent IV dose because a substantial portion of an oral dose is metabolised before it reaches systemic circulation.
Nitroglycerin given sublingually for acute angina works within minutes because the sublingual route avoids the portal circulation; the same drug given orally would be almost entirely inactivated by the liver before it could relieve chest pain, which is why nitroglycerin is never prescribed as a plain oral tablet for acute episodes. Lidocaine is never given orally as a systemic antiarrhythmic for this same reason; its first-pass metabolism is so extensive that oral dosing cannot achieve a reliable blood level.
Summary
First-pass metabolism is the loss of active drug as an oral dose passes through the gut wall and liver before reaching systemic circulation, and it explains why oral and IV doses of the same drug are rarely equal. Routes that bypass the portal circulation, such as sublingual, transdermal, and IV, avoid or reduce this effect, while prodrugs depend on it to become active at all.
At the bedside, use first-pass metabolism to question route-to-route dose conversions and to anticipate onset speed. On the exam, look past the terminology for stems describing dose mismatches by route or hepatic-dependent drug activation, since both are testing this single concept from different angles.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why is the oral morphine dose so much higher than the IV dose?
Oral morphine undergoes extensive first-pass metabolism in the liver before reaching systemic circulation, so a large fraction of the dose is inactivated before it can act. IV morphine bypasses this step entirely, which is why oral doses are typically two to three times the equivalent IV dose.
Does first-pass metabolism affect IM or subcutaneous injections?
No. IM and subcutaneous routes are absorbed into systemic circulation rather than the portal vein, so they bypass hepatic first-pass metabolism in the same way IV administration does. Onset is slower than IV because absorption from tissue takes time, but bioavailability is not reduced by the liver first.
How does liver disease change first-pass metabolism?
Reduced hepatic enzyme function or reduced hepatic blood flow, both common in liver disease, means less drug is metabolised on the first pass, so more active drug reaches systemic circulation than expected. For drugs normally subject to extensive first-pass metabolism, this can raise blood levels and toxicity risk even at a standard oral dose.
Why is codeine sometimes ineffective for pain relief?
Codeine is a prodrug that requires hepatic conversion by CYP2D6 to morphine to produce analgesia. Patients who are poor metabolisers at this enzyme convert little codeine to morphine and get minimal pain relief, while ultra-rapid metabolisers can experience unexpectedly strong or toxic effects from a standard dose.
Is first-pass metabolism the same as hepatic clearance?
No. First-pass metabolism happens before a drug reaches systemic circulation for the first time, specifically during absorption from the gut. Hepatic clearance refers to the liver's ongoing removal of drug already circulating in the blood, and it continues for as long as the drug is present regardless of route.
More on pharmacology
Guides on this